Monitor the conference call at 8:30am ET for additional detail and FDA feedback. Stock could react positively given compelling efficacy in a high-need indication, but early-stage data (n=3) warrants caution. Track enrollment updates and any FDA IDE expansion announcements.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $1.02entry
- T+1 · 6mo ago 0.00%α +0.14% · $1.02
- T+5 · 6mo ago 0.00%α +0.09% · $1.02
- T+20 · 5mo ago 0.00%α +0.30% · $1.02
- T+60 · 3mo ago +230.39%α +226.00% · $3.37
Price Chart
How similar events traded
Executive Summary
Alpha Tau announced interim results from its U.S. Alpha DaRT recurrent glioblastoma trial (REGAIN) showing 100% local disease control and 67% complete response rate in the first three patients, with one resolved grade 3 SAE. The data is early but highly promising for a deadly cancer with limited treatment options, potentially de-risking the ongoing trial and expanding Alpha Tau's pipeline.
Key Facts
- 100% local disease control in first three recurrent GBM patients treated with Alpha DaRT
- 67% complete response rate: two patients had total disappearance of enhancing tumor lesions
- One grade 3 SAE (seizure with temporary paralysis) resolved with steroids; no unanticipated SAEs
- FDA requested interim safety analysis before expanding IDE; results support trial continuation
- Trial enrollment expected up to 10 U.S. patients; primary endpoint is feasibility and safety
Financial Impact
No financial figures disclosed; pre-revenue stage. Positive clinical data may increase probability of regulatory success and partnership value.
Risk Factors
- Very small sample size (n=3) limits statistical reliability
- Alpha DaRT not yet approved for any indication; regulatory path uncertain
- Company has limited cash runway per prior 20-F; potential dilution risk
- Historical stock performance on positive news has been weak (previous high-score reports led to declines)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-054165 |
| Document: ea0290048-6k_alpha.htm | 0001213900-26-054165 |
| Document: 0001213900-26-054165-index-headers.html | 0001213900-26-054165 |
| Document: 0001213900-26-054165-index.html | 0001213900-26-054165 |
| Document: 0001213900-26-054165.txt | 0001213900-26-054165 |
Track record
14 reports on DRTSW
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Viewing Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers